Your competition already has a aGVHD deal about to drop early 2019 with a global major, and based on Phase 1 only, they are heading into 3x P2 trials already 2019....one fully funded in Oz...something MSB has failed to achieve,
How can an upstart like CYP do 3x Phase 2 2019 after only "1" phase 1 trial. ...this is your main issue...look at the 3 years chart, the 10 year chart, maybe the market is telling you something?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |